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Abstract
Three-dimensional (3D) printing holds tremendous potential as a tool for patient-specific devices. This proof-of-
concept study demonstrated the feasibility, antimicrobial properties, and computed tomography (CT) imaging
characteristics of iodine/polyvinyl alcohol (PVA) 3D meshes and stents. Under scanning electron microscopy,
cross-linked PVA displays smoother and more compacted filament arrangements. X-ray and transaxial CT images
of iodized PVA vascular stents show excellent visibility and significantly higher Hounsfield units of radiopacity
than control prints. Three-dimensional PVA prints stabilized by glutaraldehyde cross-linking and loaded with
iodine through sublimation significantly suppressed Escherichia coli and Staphylococcus aureus growth in human
blood agar disk diffusion assays. It is suggested that PVA 3D printing with iodine represents an important new
synthetic platform for generating a wide variety of antimicrobial and high-visibility devices.
Keywords: three-dimensional printing, personalized medicine, antimicrobials, iodinated contrast, computed
tomography
Introduction
Three-dimensional (3D) printing with antimicrobial
properties is still in its infancy, with only a limited number
studies published that demonstrate the potential of 3D-
printed antimicrobial materials.1–6 Many recent antibacte-
rial 3D printing methods have focused on preprint loading
methods, including surface coatings, preloaded filaments,
and resins. By comparison, iodine has been used as an ef-
fective antimicrobial wound care agent for >180 years, and
adaptation of new fabrication technologies that incorporate
iodine may offer potent and novel anti-infective strategies.7
Polymer–iodine complexes, known as iodophors, are
currently in use as antiseptics and in wound care dressings to
prevent infection.8–11 Povidone iodine (PVP-I) is one of the
most widely used iodophors, and in vitro and in vivo stud-
ies have long demonstrated that PVP-I is highly effective
against a broad spectrum of bacterial wound isolates and even
antibiotic-resistant species.12–16 PVP-I is available in many
different formulations including solutions, creams, oint-
ments, sprays, and wound dressings and there is evidence that
PVP-I may even improve wound healing. In one human case
study, PVP-I significantly increased the healing rate and re-
duced healing time in leg ulcers compared with other con-
ventional antiseptics (silver sulfadiazine and chlorhexidine
digluconate).14
This research explored a similar polymer, polyvinyl al-
cohol (PVA), as a custom 3D print platform for iodization.
PVA is a multifunctional polymer, compatible with 3D
printing techniques, such as fused deposition modeling. Im-
portantly, PVA is a water soluble synthetic polymer, similar
to PVP, which is capable of forming a molecular inclusion
complex with iodine. PVA loaded with iodine (PVA-I) has
already been used effectively in iodized foams in wound care
management and has a unique color change property that
allows for visual detection of iodine depletion.17 Iodized
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PVA materials are initially black/brown and as the iodine is
depleted, the scaffold returns to its natural color, which
ranges from clear to a cream yellow.
Iodine is also widely applied as an intravascular contrast
agent used for computed tomography (CT), angiography,
and fluoroscopy imaging due to its intrinsic ability to atten-
uate X-radiation.18 Incorporation of iodine has been used in
experimental settings for some time in construction of vari-
ous polymers with the purpose of increasing or facilitating
radiodensity.19–21
Reports show that constructed embolic materials (tested in
sheep aortas) demonstrate excellent visibility.19 A variety of
different iodine containing polymers were tested within sheep
aortas and their visibility was determined both by spectroscopy
and by fluoroscopic observation.19 They concluded that spe-
cific isomers of iodine (4-iodo- and 2,3,5-triiodobenzoyl)
along with esters synthesized in cellulose achieved high iodine
concentrations and radiopacity, whereas isomers and solvents
that failed to sufficiently incorporate iodine did not achieve
radiopacity.19 Despite these findings, iodine-containing tem-
porary or permanent medical implants are not yet extensively
used in clinical practice, reflecting concerns about local and
systemic toxicity as well as contrast-induced nephropathy.22,23
Although there is abundant evidence to support these
types of iodophors as effective antimicrobial agents, some
clinicians have expressed reluctance over iodine’s cyto-
toxicity, which depends on iodophor concentration and the
rate and mechanism of iodine release.17 Advanced tech-
nologies, such as 3D printing, may overcome many of these
issues through localizing iodine delivery, allowing for more
customized wound care scaffolds to be fabricated to patient-
specific anatomies, and adjusting iodine-dosing concentra-
tions tailored to the nature of the wound, type, and size.
In this study, we successfully 3D-printed PVA devices,
cross-linked the PVA, and then iodized the prints through
gaseous sublimation. This approach provides a highly acces-
sible, inexpensive, and ‘‘tunable’’ architecturally diverse
synthetic platform for producing antimicrobial and radiopaque
devices and meshes.
Materials and Methods
Synthesis of iodized PVA scaffolds
PVA filaments (AquaSolve, Formfutura, Nijmegen, The
Netherlands, 1.75 mm diameter) were 3D printed into mesh
patterns at 201C using a consumer grade MakerBot re-
plicator desktop 3D printer (MakerBot Industries LLC,
Brooklyn, NY). For control and experimental samples, cir-
cular disks (6.0 mm diameter and 0.8 mm thickness) were cut
from the 3D-printed meshes using a sterile hole punch before
iodine loading, electron microscopy, and agar disk diffusion
antibacterial assays. Additional PVA samples were immersed
in distilled water, dried at 25C (1 h), and cross-linked by
placing the PVA models in a gas vapor desiccator containing
two separate 50 mL containers containing (1) 20 mL of 4%
glutaraldehyde (GA) (EMD Millipore Corporation, Darm-
stadt, Germany) and (2) 10 mL of concentrated hydrochloric
acid (Fisher Scientific, Hampton, NH) at 42C for 24 h.
Cross-linked PVA scaffolds were then rinsed extensively
in distilled water and air dried for 24 h. For iodine loading,
PVA and cross-linked PVA (PVA-X) meshes were placed
in a closed 20 mL volume glass chamber containing 110 mg
of iodine crystals (Mallinckrodt Pharmaceuticals, St. Louis,
MO). The samples were incubated at 42C for 24 h to produce
gaseous iodine through sublimation, which generated PVA-I
and PVA-X loaded with iodine (PVA-X-I). Iodized samples
were next removed from the chamber and air dried for 24 h.
Vascular Y-stents were also printed with PVA and subjected to
the same cross-linking and iodine-loading procedures for CT
imaging.
Scanning electron microscopy and X-radiation imaging
Three-dimensional printed surface topographies were
characterized with an S-4800 field-emission scanning elec-
tron microscope (SEM) (HITACHI, Tokyo, Japan). Samples
were mounted on double-sided adhesive carbon tape and
attached to the working stage. X-ray imaging was accom-
plished using an OEC 9900 Elite C-Arm System by General
Electric (Fairfield, CT).
Image acquisition with CT
Transaxial CT images of the iodine-impregnated scaffolds
of simulated Y-vascular stents were acquired using a Siemens
Biograph PET/CT scanner (Siemens, Munich, Germany)
with 120 kVp and slice thickness of 0.6 mm. Coronal and
sagittal reconstructions were constructed at the image ac-
quisition workstation. Images were analyzed using Osirx
(Pixmeo SARL, Bernex, Switzerland) and Vitrea Enterprise
Suite (Vital Images, Inc., Minnetonka, MN). Hounsfield units
(HU) of each scaffold were measured using a small elliptical
region of interest. Three HU were acquired for each of the
four scaffolds. Mean HU for each scaffold were compared
with one another using Student’s t-test.
Evaluation of antimicrobial potential
of iodized PVA scaffolds
Escherichia coli and Staphylococcus aureus were used to
create 0.5 McFarland standard bacterial suspensions, and
50 lL of suspension was added to human blood agar plates
for incubation with samples. Each series was tested in trip-
licate and incubated for 24 h at 37C. Paper disks were loaded
with 10 lL of Triadine PVP-I solution (Triad Group, Inc.,
Brookfield, WI) and also tested with 3D-printed samples. For
all disk diffusion assays, the bacterial zones of inhibition
(ZOI) were measured with a digital caliper. Mean ZOI for
each sample type were compared with one another using
Student’s t-test for both E. coli and S. aureus.
Results
Cross-linking effect on 3D-printed PVA surfaces
The utility of iodine gas sublimation as a 3D-printed
PVA surface modification with antibacterial properties
was confirmed in a series of experiments designed to
characterize its material properties, interface, and anti-
bacterial inhibitory responses to Gram-negative and Gram-
positive bacteria. SEM micrographs showed a smoother
and more compact filament topography in cross-linked
PVA polymer networks than in the noncross-linked PVA
polymer networks (Fig. 1A–D). The iodized PVA prints were
also shown to be radiopaque when viewed under X-ray im-
aging (Fig. 2A, B).















































Imaging capability of 3D PVA stents
For imaging studies, vascular Y-stents made of PVA-I and
PVA-X-I were evaluated and found to be dense and readily
visible by CT. By comparison, PVA and PVA-X were sig-
nificantly less dense and required windowing to achieve
visibility on CT (Fig. 3). Quantitatively, PVA-I and PVA-X-I
were found to have significantly higher HU than PVA and
PVA-X (1666.3 and 1120.7 HU vs. 10.7 and 63.0 HU;
p < 0.0001 in both comparisons). PVA-I mean HU of 1666.3
were significantly higher than PVA-X-I mean HU (mean HU
1120.7; p < 0.0001). There was no significant difference in
HU with PVA compared with PVA-X ( p = 0.10).
Effect of 3D PVA type on bacteria growth
For antibacterial testing, PVA-I and PVA-X-I were found
to release sufficient iodine to inhibit both Gram-negative and
Gram-positive bacterial growth during agar disk diffusion
assays (Fig. 4). For all experiments, the PVA and PVA-I fully
dissolved, whereas the PVA-X and PVA-X-I versions
maintained hydrogel cross-linked formations. PVA-I meshes
inhibited bacterial growths with a mean – standard deviation
ZOI of 11.70 – 0.50 mm (n = 3) for E. coli and 13.63 – 0.58 mm
(n = 3) for S. aureus. PVA-X-I meshes inhibited bacte-
rial growth with a mean – standard deviation ZOI of 12.76 –
1.06 mm (n = 3) for E. coli and 12.70 – 0.60 mm (n = 3) for S.
aureus. PVA and PVA-X displayed no ZOI. The PVP-I
inhibited bacterial growth with a mean – standard deviation
ZOI of 8.20 – 0.04 mm (n = 6) for E. coli and 8.88 – 0.65 mm
(n = 6) for S. aureus.
When compared with PVP-I filter paper disks, all samples
(PVA, PVA-X, PVA-I, and PVA-X-I) were significantly
FIG. 1. Scanning electron microscopic images of (A) PVA, (B) PVA-X, (C) PVA-I, and (D) PVA-X-I. PVA, polyvinyl
alcohol; PVA-X, cross-linked PVA; PVA-I, PVA loaded with iodine; PVA-X-I, PVA-X loaded with iodine.
FIG. 2. X-ray images of (A) PVA-X and (B) PVA-X-I.















































different ( p < 0.0001). For PVA-I versus PVA-X-I, no sig-
nificant differences were found for the ZOI (E. coli
p = 0.1923, S. aureus p = 0.1141). For the PVA versus PVA-I
ZOI, there were significant differences for both E. coli and S.
aureus (P < 0.0001). For the PVA-X versus PVA-X-I, sig-
nificant differences were also noted for both E. coli and S.
aureus ( p < 0.0001).
Discussion
Three-dimensional printing techniques have already
enormous utility in many industrial applications and are
viewed as important tools in future clinical technology de-
velopment. Medical applications for 3D printing are rapidly
expanding and soon may replace many conventional bio-
material manufacturing approaches, as customizable and
on-demand wound care products with localized drug de-
livery have many diverse applications.24 A wide range of
materials are being explored for medical applications in 3D
printing, which include plastics, metals, ceramics, and bi-
ological materials.25 The current era of rapid prototyping
and the rapidly expanding catalog of compatible materials
are expanding the potential for new tissue and organ fabri-
cation techniques in transplantation, as well as new phar-
maceuticals and drug delivery systems.26,27
Iodine-containing 3D-printed scaffolds were found to have
significantly higher HU and demonstrated superior visibility
on CT. Although the iodine-containing scaffolds without
cross-linking (PVA-I) had significantly higher HU (than the
cross-linked iodine-containing scaffolds (PVA-X-I), this is not
likely to be highly meaningful clinically as both were well
visible (i.e., highly radiodense) on CT. In this study, we choose
an atypical configuration of a vascular stent (Y-stent) as a
proof on principle and to add dimensions/complexity to our
3D-printed constructs. In this format, the principle of iodine-
containing customizable devices again demonstrates the value
of iodination in custom-constructed 3D-printed implants.
Therefore, in addition to radiopacity, the iodination of
implants (e.g., vascular stents) may create materials that have
the ability to reduce or eliminate colonization with bacteria
(i.e., ‘‘nidus’’ of infection) and to reduce the risk of localized
infection associated with implantation of foreign materials.
FIG. 3. CT image acquisition of iodine-impregnated and control 3D-printed vascular Y-stent substrates (A–C). Transaxial
(A) CT images of the 3D-printed substrate with coronal (B) and 3D coronal reconstructions. (D) Illustration of acquiring the
Hounsfield units data using an elliptical region of interest on the PVA-I stent. Color image displaying (E) PVA, (F) PVA-X,
(G) PVA-I, and (H) PVA-X-I stents. Color images available online at www.liebertpub.com/3dp















































Three-dimensional printing offers the ability to fabricate
custom implants with tailored concentrations of iodinated
material for imaging and antimicrobial applications.
The nature of additive manufacture is such that an iodine-
containing layer can be created within the scaffold for ex-
tended release or long-term imaging. Through additional
polymer coatings, which can be permanent or slow degrading,
the iodine prints can be shielded from the outside (reducing
toxicity). These additional layers and porous scaffolds can
potentially provide more surface area to increase or customize
the overall iodine content of a given construct. If a construct is
impregnated with iodine for imaging purposes only, the deeper
filaments can have higher concentrations of iodine, whereas
the more superficial layers could be manufactured with lower
concentrations or even completely free of iodine.
Alternatively, if elution of iodine is desired, iodine con-
centration can be maintained uniform throughout the con-
struct. With bioabsorbable plastics, this would potentially
unmask a ‘‘new’’ coating of iodine every time the most su-
perficial layer dissolves.6,28 In addition, the use of iodine
sublimation with printed PVA matrixes allows derivatization
in solid phase and avoids the need for aqueous I2/KI mixtures
that might dissolve or warp these matrices. Although iodine
complexed with PVA in this manner may have antimicrobial
and visibility properties, testing of this material is needed to
determine any limitations to its practical applications for
routine clinical use.
Although nephrotoxicity associated with iodinated intra-
vascular contrast media is well described, recent data suggest
its warnings may have somewhat overestimated risk com-
pared with prior estimates.22,23 Imaging of iodine diffusion
into adjacent tissues might be used to measure iodine abun-
dance, also may be advantageous in nonvascular antimicro-
bial applications (e.g., iodine-impregnated devices in a
nonvascular postoperative cavity).
The refinements of 3D-printed implant approaches will
allow their introduction into clinical practice; however, they
are not yet well defined, especially with bioactive printing
(i.e., impregnating drugs or compounds into an implant or
instrument’s structure). The United States Food and Drug
Administration has published its own perspectives on this
topic, addressing known and unknown issues regarding regu-
lation of 3D-printed materials within medical use.29 Although
3D-printed models and some implants have demonstrated
value by reducing operating room time,30,31 more research is
needed to validate this, especially when considering bioactive
3D printing, which has not been extensively evaluated in hu-
mans at the time of writing.28
In this study, we did not study the effect of sterilization
techniques and their potential effect on the composition of the
iodine-containing substrates. Options for printing sterile im-
plants in 3D printing include printing all material in a sterile
environment or chemical sterilization, with compounds such
as GA.28,32 Another limitation to applying the present data and
FIG. 4. Charts displaying the zones of inhibition for substrates against (A) Escherichia coli and (B) Staphylococcus aureus
in blood agar disk diffusion assays. Images show 3D-printed PVA-X-I samples in blood agar disk diffusion assays against
(C) E. coli and (D) S. aureus. The dotted circle in (C) and (D) represents the 3D print perimeter and the double-headed
arrow represents the zone of inhibition.















































concepts in animals or humans is that it is unknown whether
the visibility in the constructs will be maintained over time,
after implantation. Future study designs in animals or humans
should obtain initial imaging and compare the visibility or HU
with imaging taken over several days to weeks. In addition,
in vivo implantation may have an immediate effect on X-ray
attenuation compared with the in vitro data obtained in
this study.
Commercial iodine wound dressing materials have been
previously studied with various microorganisms.33 The mean
ZOI reported for iodine dressings against S. aureus was
14 mm, which suggests that 3D-printed PVA-I and PVA-X-I
are comparable with commercial grade wound dressings and
hold tremendous potential in antimicrobial applications.33
Conclusions
To our knowledge, this is the first report showing that post-
3D-printed materials can be loaded with iodine through
sublimation to exhibit microbiostatic and radiopaque prop-
erties. The sublimation process produced molecular iodine
gas, which reacted with the PVA hydroxyl groups to form
PVA iodine complexes. It is apparent that GA cross-linking
appears to reduce at least some of potential binding sites
where iodine interacts with PVA; however, cross-linking
generates a PVA hydrogel scaffold with much greater hy-
drophilic lifetime, enabling extended release. Using this
method, we anticipate that a large variety of wound care
products may be fabricated that can be modified for localized
delivery of different rates of iodine release with different
intensities of antimicrobial activity.
The realization of scalable and cost-effective antimicrobial
biomaterial fabrication techniques may provide clinicians
with a new and powerful arsenal of antimicrobial materials.
These methods may also be potentially used with larger
custom sublimation chambers to synthesize iodized 3D-
printed PVA objects at an industrial-scale amount or produce
relatively smaller in-house productions at healthcare facilities.
Overall, the iodized 3D print created through sublimation
provides a foundation for future researchers to explore and has
potential uses as medical devices, wound dressings, and anti-
microbial surfaces.
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